Bianca Maria Messina

Dr. Bianca Maria Messina

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
BMBianca Maria Messina
Bianca Maria Messina
Cristina GrippaudoCristina Grippaudo
Cristina Grippaudo
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
Andrea BlasiAndrea Blasi
Andrea Blasi
Gaetano IsolaGaetano Isola
Gaetano Isola
New technologies and tools are emerging in periodontology and oral health. Periodontitis is a chronic inflammatory condition that destroys the supporting tissues of the teeth and ultimately leads to tooth loss. As one of the most prevalent oral conditions, periodontitis endangers the oral health of 70% of people worldwide, and has been increasingly linked to various systemic diseases. In this regard, Porphyromonas gingivalis (P. gingivalis) is a key pathogen in the oral microbiome and a Gram-negative oral anaerobic bacterium that plays a key role in the pathogenesis of periodontitis. Porphyromonas gingivalis can express various virulence factors to evade innate and adaptive immunities, which causes P. gingivalis to survive and propagate in the host, destroy periodontal tissues, and contribute to systemic diseases. This narrative review aims to summarize the current knowledge on the impact of P. gingivalis in oral microbiome formation and its mechanistic links to systemic diseases such as cardiovascular disease, diabetes mellitus, rheumatoid arthritis, and Alzheimer’s disease. This review will explore the pathogenic mechanisms employed by P. gingivalis, including immune evasion, dissemination, and molecular mimicry, and evaluate the clinical and epidemiological evidence linking periodontitis with systemic health outcomes. By consolidating these insights, this review seeks to highlight the importance of periodontal health in preventing systemic diseases and propose potential therapeutic interventions targeting P. gingivalis. These findings highlight that early diagnosis and effective treatment of periodontitis, particularly targeting P. gingivalis, are essential not only to preserving oral health but also to reducing the risk and progression of systemic diseases.

4 December 2025 in Life
Verified
Journal Article
Open access
PDF file
BMBianca Maria Messina
Bianca Maria Messina
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
cristina panuzzocristina panuzzo
cristina panuzzo
ABAntonio Belmonte
Antonio Belmonte
AAAngela Angjelova
Angela Angjelova
Gaetano IsolaGaetano Isola
Gaetano Isola
Host-modulating therapies and oral microbiome-targeted approaches are emerging options in periodontal care and are especially relevant for patients undergoing immunotherapy for hematologic malignancies. Immune dysregulation induced by immune checkpoint inhibitors or CAR-T cell therapy may worsen periodontal inflammation and alter the composition and functions of the oral microbiota. Beyond these, other immunomodulatory treatments commonly employed in hematologic malignancies—including monoclonal antibodies (e.g., rituximab, daratumumab), immunomodulatory drugs (e.g., lenalidomide, thalidomide), cytokine-based therapies (e.g., interferon-α), and targeted small-molecule inhibitors (e.g., BTK inhibitors, JAK inhibitors) may also influence periodontal homeostasis and oral microbial ecology by altering neutrophil function, cytokine profiles, and mucosal immune surveillance. The oral microbiota is functionally connected with the intestinal microbial ecosystem through the oral–gut axis, by periodontal pathogens may colonize the gut and modulate systemic immune responses, with potential repercussions on the efficacy and safety of immunotherapy. This narrative review examines the mechanisms and clinical applicability of host-modulating therapies, including subantimicrobial-dose doxycycline, omega-3 fatty acids, and microbiome-targeted interventions, such as oral probiotics, prebiotics and other antimicrobials in patients treated with immunotherapy.